Composition Comprising Lactic Acid Bacteria Derived from Green Tea for Improving Liver Function

USPTO granted patent US12594310B2 to AMOREPACIFIC CORPORATION on April 7, 2026, covering a method for improving hepatic function using a composition derived from green tea-derived Lactiplantibacillus plantarum strain. The patent includes 6 claims and covers the strain, culture, lysate, and extracts thereof.

Method for treating liver cirrhosis using mesenchymal stem cell composition

The USPTO granted patent US12594304B2 to GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD. for a method of treating liver cirrhosis using a composition comprising mesenchymal stem cells, extracellular vesicles produced by mesenchymal stem cells, and growth factors. The patent contains 15 claims and is classified under CPC codes A61K 35/28, A61K 9/0019, and A61P 1/16.

Use of ENTPD3 for identification, isolation, and enhancing mature stem cell derived insulin-producing cells

The USPTO granted patent US12594306B2 to the Regents of the University of Colorado on April 7, 2026. The patent covers methods and compositions for identifying, sorting, and separating stem cell-derived pancreatic beta cells using the cell surface protein ENTPD3 (CD39L3) for diabetes treatment applications. The patent includes 13 claims and has a filing date of March 25, 2022.

Methods of preparing a postbiotic composition

USPTO granted patent US12594308B2 to Science Power SRL covering methods of preparing postbiotic compositions through multiple separate microbial fermentations. The patent, based on Application No. 18909568 filed October 8, 2024, includes 15 claims and lists Federica Nigro as the inventor. The composition may be produced via parallel or sequential fermentation steps.

Methods of administering safe colon cleansing compositions

USPTO granted patent US12594298B2 to Azurity Pharmaceuticals covering methods of administering colon cleansing compositions. The patent protects formulations comprising salt mixtures that induce purgation without requiring adjunct laxatives like bisacodyl, offering improved tolerability and patient compliance. The patent names Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, and Matthew Walker as inventors, with 3 claims allowed.

Philadelphia Man Charged as Repeat Offender with CSAM Distribution and Invasion of Privacy

Pennsylvania Attorney General Dave Sunday announced criminal charges against Jason Sheasley, 40, of Philadelphia, for possession and distribution of child sexual abuse material and invasion of privacy. Sheasley, a repeat offender with a 2016 New Jersey conviction, was arraigned on nine felonies and three misdemeanors with $500,000 bail set. The investigation began in January when agents discovered Sheasley sharing CSAM videos online and found evidence of unauthorized video recording of a woman.

Revenue Procedure 2026-14 - Qualified Opportunity Zone Nominations Procedure

The IRS issued Revenue Procedure 2026-14 to provide guidance to State CEOs on the procedural requirements for nominating population census tracts as Qualified Opportunity Zones (QOZs) for designation effective January 1, 2027. The guidance implements amendments made by Section 70421 of the One, Big, Beautiful Bill Act (OBBBA) to IRC Sections 1400Z-1 and 1400Z-2. Nominating authorities must follow the prescribed process to designate low-income community census tracts as QOZs.

FDA Complaint - Tracking mno-s34f-ax16

FDA received a complaint filed on April 7, 2025, tracked under identifier mno-s34f-ax16 (docket FDA-2026-H-3442-0001). The complaint was submitted by CTP (Center for Tobacco Products) and is accessible via regulations.gov. No documents are currently available for viewing or download from the docket.

FDA Suitability Petition Amendment - Hyman Phelps & McNamara

Law firm Hyman, Phelps & McNamara, P.C. filed an amendment to a suitability petition with FDA's Center for Drug Evaluation and Research (CDER). The petition seeks a regulatory determination regarding drug product suitability under the Federal Food, Drug, and Cosmetic Act. FDA will review the amended petition and issue a determination on whether the requested drug product meets suitability requirements for approval pathways.

FDA confirms STRATTERA not withdrawn for safety

FDA confirms STRATTERA not withdrawn for safety